Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS.

Citation data:

Pediatric blood & cancer, ISSN: 1545-5017, Vol: 60, Issue: 4, Page: 705-10

Publication Year:
2013
Usage 117
Abstract Views 111
Link-outs 6
Captures 9
Readers 7
Exports-Saves 2
Social Media 4
Tweets 4
Citations 10
Citation Indexes 10
PMID:
23152304
DOI:
10.1002/pbc.24390
PMCID:
PMC3668778
Author(s):
Smith, Angela R., Christiansen, Ellen C., Wagner, John E., Cao, Qing, MacMillan, Margaret L., Stefanski, Heather E., Trotz, Barbara A., Burke, Michael J., Verneris, Michael R.
Publisher(s):
Wiley-Blackwell
Tags:
Medicine
Most Recent Tweet View All Tweets
article description
Although hematopoietic stem cell transplantation (HSCT) is the treatment of choice for childhood myelodysplastic syndrome (MDS), there is no consensus regarding patient or disease characteristics that predict outcomes.

This article has 0 Wikipedia mention.